Marshall Edwards' CEO to Present at Needham Healthcare Conference
03. Juni 2010 08:00 ET
|
Marshall Edwards, Inc.
SYDNEY, AUSTRALIA and SAN DIEGO, CA--(Marketwire - June 3, 2010) - Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of novel anti-cancer...
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
19. März 2009 13:07 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Marshall Edwards, Inc. Granted IND for Triphendiol
07. Januar 2009 08:10 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has been granted an Investigative New Drug (IND) approval
by the United States Food and...
Marshall Edwards, Inc. Files IND Application for Triphendiol
01. Dezember 2008 08:10 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has filed an application with the United States Food and
Drug Administration for an...
Clinical Phase I Study Report of Marshall Edwards' Compound Triphendiol to Be Reported in ASCO Proceedings
15. Mai 2008 21:00 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - May 15, 2008) - An abstract submitted to the Annual Meeting
of the American Society of Clinical Oncology (ASCO), May 30-June 3,
Chicago, Illinois, entitled "Phase Ia...
Marshall Edwards, Inc.'s Investigational Drug Triphendiol (NV-196) Demonstrates Potent Activity Against Biliary Cancers
13. April 2008 16:00 ET
|
Marshall Edwards, Inc.
SAN DIEGO, CA--(Marketwire - April 13, 2008) - Pre-clinical studies presented here today at
the annual meeting of the American Association for Cancer Research
demonstrate that Marshall Edwards,...
Data to Be Presented at AACR Reveals That the Marshall Edwards' Compound Triphendiol May Aid in Treatment of Pancreatic Cancer
25. März 2008 08:02 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - March 25, 2008) - The abstract for a "late breaking"
presentation at the Annual Meeting of the American Association for Cancer
Research, April 12-16, San Diego, Calif.,...
Additional Orphan Drug Status Granted for Melanoma for Marshall Edwards' Investigational Anti-Cancer Drug Triphendiol (NV-196)
19. Februar 2008 07:31 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - February 19, 2008) - Marshall Edwards, Inc., (NASDAQ: MSHL)
announced today that triphendiol (previously known as NV-196) has been
granted Orphan Drug status by the U.S....